Zusammenfassung
Ropinirol ist ein nicht-ergoliner Dopamin-Agonist mit mittellanger Halbwertzeit, der
seit über 10 Jahren zur Therapie des idiopathischen Parkinson-Syndroms in der Mono-
und Kombinationstherapie zugelassen ist. Seit 2008 ist in Deutschland auch die retardierte
Formulierung (PR = prolonged release) zugelassen, die eine Einmalgabe pro Tag ermöglicht.
Hiermit werden geringere Plasmaspiegel-Schwankungen als mit der 3 × täglichen Gabe
der nicht retardierten Formulierung erzielt und eine gleichmäßigere dopaminerge Therapie
mit symptomatischer Wirksamkeit am Tag und in der Nacht ermöglicht. Ropinirol PR hat
sich in kontrollierten Studien in der Monotherapie bei Parkinson-Patienten im Frühstadium
und als Add-on-Therapie bei Patienten im fortgeschrittenen Stadium als gut wirksam
und verträglich erwiesen. Im direkten Vergleich beider Formulierungen als Add-on-Therapie
zu L-Dopa bei Patienten in fortgeschrittenem Krankheitsstadium wurden unter Ropinirol
PR höhere Dosierungen erreicht bei höherer L-Dopa-Einsparung. Dies war mit einer signifikant
besseren Wirksamkeit verbunden. Ropinirol PR kann rascher eindosiert werden. Bereits
in der zweiten Therapiewoche wird eine signifikante Wirksamkeit erzielt. Insbesondere
bei Patienten mit vorbestehender Parkinson-bedingter Schlafstörung wurden günstige
Effekte auf den Schlaf bzw. nächtliche Symptome nachgewiesen.
Abstract
Ropinirole is a non-ergoline dopamine agonist with medium elimination half time, which
has been licenced for the therapy of idiopathic Parkinson syndrome in mono- and add-on
therapy for more than 10 years. Since 2008 a prolonged-release formulation has been
available in Germany, which can be taken once daily. This formulation results in less
plasma level fluctuations compared to the thrice-daily immediate-release formulation
enabling smoother dopaminergic therapy with symptomatic efficacy day and night. Ropinirole
PR has shown good efficacy and tolerability in controlled trials in monotherapy in
early patients as well as in add-on studies in advanced patients. In a head-to-head
comparison of both formulations as add-on therapy in advanced patients higher doses
were achieved with ropinirole PR accompanied by a higher mean decrease of L-Dopa dose.
Under these conditions significantly higher efficacy was observed. The titration regime
of ropinirole PR is faster with significant efficacy versus placebo as early as in
week 2. Especially in patients with pre-existing Parkinson-related poor sleep quality
positive effects on sleep and nocturnal symptoms were shown.
Schlüsselwörter
idiopathisches Parkinson-Syndrom - Dopamin-Agonist - Ropinirol - Parkinson-bedingte
Schlafstörung
Keywords
idiopathic Parkinson syndrome - Ropinirole - dopamine agonist - Parkinson-related
poor sleep quality
Literatur
- 1
Jost W H, Angersbach D, Rascol O.
Clinical studies with ropinirole in Parkinson’s disease and RLS.
J Neurol.
2006;
253 (Suppl 4)
IV/ 16-IV/ 21
- 2
Olanow C W, Obeso J L, Stocchi F.
Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale
and clinical implications.
Lancet Neurol.
2006;
5
677-687
- 3
Conte U, Maggi L.
Modulation of the dissolution profiles from Geomatrix multi-layer matrix tablets containing
drugs of different solubility.
Biomaterials.
1996;
17
889-896
- 4
Tompson D, Vearer D.
Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation
of ropinirole: Results of two randomized studies in patients with Parkinson’s disease.
Clin Ther.
2007;
29
2654-2666
- 5
Stocchi F, Hersh B P, Scott B L. et al .
Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s
disease: a randomized, double-blind, non-inferiority crossover study.
Curr Med Res Opin.
2008;
24 (10)
2883-2895
- 6 Fachinformation Requip-Modutab® Retardtabletten. Stand: Februar 2008
- 7
Pahwa R, Stacy M A, Factor S A. et al .
Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson
disease.
Neurology.
2007;
68
1108-1115
- 8
Shapira A HV, Stocchi F, Hunter B. et al .
Comparison of adjunctive ropinirole prolonged release and ropinirole immediate release
in patients with advanced Parkinson’s disease: A post-hoc per-protocol analysis of
the PREPARED study.
Mov Disord.
2008;
23 (Suppl 1)
S196-S197
- 9
Rascol O, Brooks D J, Korczyn A D. et al .
A five-year study of the incidence of dyskinesia in patients with early Parkinson’s
disease who were treated with ropinirole or levodopa. 056 Study Group.
N Engl J Med.
2000;
342 (20)
1484-1491
- 10
Watts R L, Sethi K L, Pahwa R. et al .
Ropinirole 24-hours prolonged release delays the onset of dyskinesia compared with
carbidopa/levodopa in patients with Parkinson’s disease treated with levodopa. 2007.
Mov Disord.
2007;
22 (Suppl 16)
S95
- 11
Chaudhuri K R, Pal S, DiMarco A. et al .
The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal
disability in Parkinson’s disease.
J Neurol Neurosurg Psychiatry.
2002;
73
629-635
- 12
Chaudhuri K R, Giorgi L, Statham J.
Ropinirole prolonged release improves nocturnal symptoms in patients with advanced
Parkinson’s disease with sleep disturbances.
Mov Disord.
2009;
24 (Suppl 1)
S259
- 13
Stocchi F, Hunter B L, Giorgi L. et al .
Comparison of adjunctive ropinirole prolonged release and ropinirole immediate release
in patients with advanced Parkinson’s disease: The PREPARED study. 2008.
Mov Disord.
2008;
23 (Suppl 1)
S215-S216
- 14
Lyons K E, Pahwa R.
An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson’s
disease.
Mov Disord.
2009;
24 (14)
2121-2127
- 15
Grosset D, Antonini A, Canesi M. et al .
Adherence to antiparkinson medication in a multicenter European study.
Mov Disord.
2009;
24 (6)
826-832
Prof. Dr. med. Wolfgang Jost
Fachbereich Neurologie, Deutsche Klinik für Diagnostik
Aukammallee 33
65191 Wiesbaden
Email: jost.neuro@dkd-wiesbaden.de
